Turn Biotechnologies works on the same core mechanism as Altos Labs and NewLimit, partial cellular reprogramming, but differentiates on delivery method. Rather than using viral or DNA-integrating vectors to introduce reprogramming factors, which can leave permanent genetic changes in a cell, Turn's approach delivers the reprogramming instructions as mRNA: temporary, degradable, and gone once the reprogramming effect has been achieved.
That distinction goes directly to the central safety concern in reprogramming research covered in the cellular reprogramming entry: the risk that reprogramming factors, powerful enough to reset cell identity, can also promote uncontrolled cell growth if left active too long or too permanently. A transient mRNA approach is one attempt to get the rejuvenation benefit while limiting how long the cell is exposed to that risk.
The company's mRNA delivery approach also connects it to a broader trend of mRNA technology moving beyond vaccines into a general-purpose tool for temporary, controllable gene expression, an approach gaining attention across biotech for exactly the kind of dosing and reversibility control that permanent genetic interventions can't offer.